NGLFINE Stock Overview
Manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NGL Fine-Chem Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,241.80 |
| 52 Week High | ₹2,823.90 |
| 52 Week Low | ₹1,429.80 |
| Beta | 1.01 |
| 1 Month Change | -12.05% |
| 3 Month Change | 11.28% |
| 1 Year Change | 55.27% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 19.95% |
Recent News & Updates
NGL Fine-Chem's (NSE:NGLFINE) Promising Earnings May Rest On Soft Foundations
May 28
NGL Fine-Chem Limited's (NSE:NGLFINE) 26% Price Boost Is Out Of Tune With Earnings
Apr 20Recent updates
NGL Fine-Chem's (NSE:NGLFINE) Promising Earnings May Rest On Soft Foundations
May 28NGL Fine-Chem Limited's (NSE:NGLFINE) 26% Price Boost Is Out Of Tune With Earnings
Apr 20NGL Fine-Chem Limited (NSE:NGLFINE) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Nov 18Weak Statutory Earnings May Not Tell The Whole Story For NGL Fine-Chem (NSE:NGLFINE)
Nov 05Shareholder Returns
| NGLFINE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.6% | -1.8% | -1.9% |
| 1Y | 55.3% | 51.6% | 41.0% |
Return vs Industry: NGLFINE exceeded the Indian Pharmaceuticals industry which returned 54.1% over the past year.
Return vs Market: NGLFINE exceeded the Indian Market which returned 41% over the past year.
Price Volatility
| NGLFINE volatility | |
|---|---|
| NGLFINE Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: NGLFINE has not had significant price volatility in the past 3 months.
Volatility Over Time: NGLFINE's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 396 | Rahul Nachane | www.nglfinechem.com |
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, xylazine hydrochloride, and marbofloxacin for animal health applications; and nitazoxanide and atovaquone for human health applications. The company provides various intermediate products and specialty chemicals; and finished dosage forms in granules and tablets.
NGL Fine-Chem Limited Fundamentals Summary
| NGLFINE fundamental statistics | |
|---|---|
| Market cap | ₹13.78b |
| Earnings (TTM) | ₹413.17m |
| Revenue (TTM) | ₹3.53b |
33.3x
P/E Ratio3.9x
P/S RatioIs NGLFINE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGLFINE income statement (TTM) | |
|---|---|
| Revenue | ₹3.53b |
| Cost of Revenue | ₹1.59b |
| Gross Profit | ₹1.94b |
| Other Expenses | ₹1.53b |
| Earnings | ₹413.17m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 66.88 |
| Gross Margin | 55.02% |
| Net Profit Margin | 11.71% |
| Debt/Equity Ratio | 12.4% |
How did NGLFINE perform over the long term?
See historical performance and comparisonDividends
0.08%
Current Dividend Yield3%
Payout RatioDoes NGLFINE pay a reliable dividends?
See NGLFINE dividend history and benchmarks| NGL Fine-Chem dividend dates | |
|---|---|
| Ex Dividend Date | Aug 16 2024 |
| Dividend Pay Date | Sep 22 2024 |
| Days until Ex dividend | 75 days |
| Days until Dividend pay date | 112 days |
Does NGLFINE pay a reliable dividends?
See NGLFINE dividend history and benchmarks